CpG oligonucleotides suppress HepG2 cells-induced Jurkat cell apoptosis via the Fas-FasL-mediated pathway

Journal of Experimental & Clinical Cancer Research

Xiaozhong Wang¹  Jing Li²  Rongquan Fu³  Jianfeng Zheng¹ 

[1] Department of Clinical Laboratory, the Second Affiliated hospital of Nanchang University, Nanchang 330006, China;Department of Clinical Laboratory, the First Affiliated hospital of Nanchang University, Nanchang 330006, China;Department of Infectious Diseases, the Third Affiliated Hospital of Wenzhou Medical College, Rui'an 325200, China

关键词: apoptosis;    hepatocellular carcinoma;    CpG-ODN;   

Others  :  827549
DOI  :  10.1186/1756-9966-30-48

 received in 2011-02-09, accepted in 2011-05-03,  发布年份 2011

【 摘 要 】

Objective

To explore the potential role of CpG motif-containing oligonucleotides (CpG-ODN) in modulating the expression of FasL in HepG2 and Fas in Jurkat cells in vitro, and to examine the effect of CpG-ODN treatment on the HepG2 cells-mediated Jurkat cell apoptosis in vitro.

Methods

The expressions of FasL in HepG2 and Fas in Jurkat cells were examined by real time PCR and flow cytometry (FCM). HepG2 and Jurkat cells were co-cultured, and the frequency of apoptotic Jurkat cells and levels of activated caspase-3 were determined by FCM.

Results

Treatment with CpG-ODN down-regulated the expression of FasL in HepG2 cells in a dose- and time-dependent manner. In addition, treatment with CpG-ODN down-regulated the Fas mRNA transcription and protein expression in Jurkat cells. Treatment of HepG2 cells or Jurkat cells with FasL-neutralizing antibody NOK-2 remarkably inhibited the HepG2-medaited Jurkat cell apoptosis. Pre-treatment of HepG2 or Jurkat cells with CpG-ODN significantly reduced the frequency of HepG2-mediated apoptotic Jurkat cells and inhibited the activation of caspase-3 in Jurkat cells in vitro.

Conclusions

Our data indicated that treatment with CpG-ODN inhibited the HepG2 cells-mediated Jurkat cell apoptosis by modulating the Fas/FasL pathway. Apparently, CpG-ODN treatment may be a potential therapeutic reagent for HCC.

【 授权许可】

   
2011 Zheng et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Vicari AP, Caux C, Trinchieri G: Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002, 12:33-42.
• [2]Gratas C, Tohma Y, Barnas C, Taniere P, Hainaut P, Ohgaki H: Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer. Cancer Res 1998, 58:2057-62.
• [3]Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K, Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004, 114:560-8.
• [4]Roman M, Martin-Orozco E, Goodman JS, et al.: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997, 3:849-54.
• [5]Sparwasser T, Vabulas RM, Villmow B, Lipford GB, Wagner H: Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur J Immunol 2000, 30:3591-7.
• [6]Heckelsmiller K, Beck S, Rall K, et al.: Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur J Immunol 2002, 32:3235-45.
• [7]Okamoto M, Sato M: Toll-like receptor signaling in anti-cancer immunity. J Med Invest 2003, 50:9-24.
• [8]Wooldridge JE, Weiner GJ: CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response. Curr Opin Oncol 2003, 15:440-5.
• [9]Thorgeirsson SS, Teramoto T, Factor VM: Dysregulation of apoptosis in hepatocellular carcinoma. Semin Liver Dis 1998, 18:115-22.
• [10]Lau SH, Guan XY: Cytogenetic and molecular genetic alterations in hepatocellular carcinoma. Acta Pharmacol Sin 2005, 26:659-65.
• [11]Park YN, Chae KJ, Kim YB, Park C, Theise N: Apoptosis and proliferation in hepatocarcinogenesis related to cirrhosis. Cancer 2001, 92:2733-8.
• [12]Hou L, Li Y, Jia YH, et al.: Molecular mechanism about lymphogenous metastasis of hepatocarcinoma cells in mice. World J Gastroenterol 2001, 7:532-6.
• [13]Hartmann G, Battiany J, Poeck H, et al.: Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol 2003, 33:1633-41.
• [14]Ramakers C, Ruijter JM, Deprez RH, Moorman AF: Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 2003, 339:62-66.
• [15]Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H: Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's C (T) difference" formula. J Mol Med 2006, 84:901-10.
• [16]Kim R, Emi M, Tanabe K, Uchida Y, Toge T: The role of Fas ligand and transforming growth factor beta in tumor progression: molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy. Cancer 2004, 100:2281-91.
• [17]Muppidi JR, Siegel RM: Ligand-independent redistribution of Fas (CD95) into lipid rafts mediates clonotypic T cell death. Nat Immunol 2004, 5:182-9.
• [18]Lam HK, Li K, Chik KW, et al.: Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia. Int J Oncol 2005, 27:537-45.
• [19]Ghobrial IM, Witzig TE, Adjei AA: Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005, 55:178-94.
• [20]Takeda K, Akira S: TLR signaling pathways. Semin Immunol 2004, 16:3-9.
• [21]O'Connell J, O'Sullivan GC, Collins JK, Shanahan F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996, 184:1075-82.
• [22]Lim EJ, Park DW, Lee JG, et al.: Toll-like receptor 9-mediated inhibition of apoptosis occurs through suppression of FoxO3a activity and induction of FLIP expression. Exp Mol Med 2010, 42(10):712-20.
• [23]Guo LH, Schluesener HJ: Binding and uptake of immunostimulatory CpG oligodeoxynucleotides by human neuroblastoma cells. Oligonucleotides 2004, 14:287-98.